Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI)
Conditions
- Cancer Treated With Immune-checkpoint Inhibitors
Interventions
- DRUG: nivolumab monotherapy
- DRUG: nivolumab plus ipilimumab
Sponsor
Institut Bergonié
Collaborators